Insight Molecular Diagnostics Inc.
IMDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.01 | 0.06 | -0.05 |
| FCF Yield | -68.24% | -123.41% | -140.32% | -19.79% |
| EV / EBITDA | -0.44 | -0.54 | -1.44 | -3.36 |
| Quality | ||||
| ROIC | -209.76% | -36.41% | -20.08% | -13.29% |
| Gross Margin | 39.34% | 33.33% | 8.14% | 8.55% |
| Cash Conversion Ratio | 0.34 | 0.84 | 0.63 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 25.22% | -11.90% | -7.64% | – |
| Free Cash Flow Growth | 10.07% | 52.70% | -30.69% | -40.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | 0.28 | 1.24 | 0.62 |
| Interest Coverage | -726.68 | -483.38 | -216.83 | -113.75 |
| Efficiency | ||||
| Inventory Turnover | 2.78 | 0.00 | 0.46 | 24.80 |
| Cash Conversion Cycle | -284.89 | -201.59 | 1,091.19 | 165.72 |